Kawakami S, Fukui I, Yonese J, Ueda T, Ohno Y, Tsuzuki M, Kawai T
Department of Urology, Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo, Japan.
Urol Int. 1997;59(4):243-7. doi: 10.1159/000283072.
The relative risk for a second primary cancer after the diagnosis of prostate cancer and the prognostic impact of the association of multiple primary malignant neoplasms (MPMNs) in patients with prostate cancer were analyzed in a retrospective study. The development of MPMNs was examined in 312 consecutive patients who had been diagnosed with prostate cancer between 1966 and 1992. The population-based cancer incidence rates in Japan were utilized to calculate the expected number of MPMNs. Of the 312 patients, 60 fulfilled the diagnosis of MPMNs. In 13 men, prostate cancer and other malignancies were diagnosed simultaneously. In 35 of the 312 patients, prostate cancer was the second or third cancer diagnosis. In the remaining 287 patients, prostate cancer developed initially. Of the 287 patients, 12 developed a second primary malignancy compared with 17 expected (relative risk 0.71, 95% confidence interval 0.45-1.4). No single anatomic site showed a significantly increased risk above that expected either. The overall survival of patients with prostate cancer was not reduced by the association with MPMNs. This may be explained by the fact that the stage of the prostate cancer was lower in patients with MPMNs than in patients without MPMNs.
在一项回顾性研究中，分析了前列腺癌诊断后发生第二原发性癌症的相对风险以及前列腺癌患者中多原发性恶性肿瘤（MPMN）关联的预后影响。在1966年至1992年间连续诊断出前列腺癌的312例患者中检查了MPMN的发生情况。利用日本基于人群的癌症发病率来计算MPMN的预期数量。在这312例患者中，60例符合MPMN的诊断标准。在13名男性中，前列腺癌和其他恶性肿瘤同时被诊断出来。在312例患者中的35例中，前列腺癌是第二次或第三次癌症诊断。在其余287例患者中，前列腺癌最初发生。在这287例患者中，12例发生了第二原发性恶性肿瘤，而预期为17例（相对风险0.71，95%置信区间0.45-1.4）。也没有单一解剖部位显示出高于预期的显著增加的风险。前列腺癌患者的总生存率并未因与MPMN的关联而降低。这可能是因为MPMN患者的前列腺癌分期低于无MPMN的患者。
